Drawing for RETHYMIC

USPTO serial 88319658

RETHYMIC

Reviewed by CopyMark Law Group

Reg. 6026670Status 702Registered
Filing date
Status date
Registration date
Apr 7, 2020
Examiner
AVENT, TEAGUE A
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with RETHYMIC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey R. Cadwell

Jeffrey R. Cadwell Dorsey & Whitney LLP50 South Sixth Street, Suite 1500Minneapolis, MN 55402-1498United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for human use for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; pharmaceutical preparations for human use, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related theretoACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 1, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Jul 1, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jun 29, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 3, 2026ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Apr 1, 2026E815TEAS SECTION 8 & 15 RECEIVED—
Mar 18, 2026ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Apr 7, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Apr 7, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 21, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 21, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 1, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 13, 2019FIXDELECTRONIC RECORD REVIEW COMPLETE—
Dec 6, 2019ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Dec 4, 2019ALIEASSIGNED TO LIE—
Dec 1, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 11, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 9, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 9, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 25, 2019DOCKASSIGNED TO EXAMINER—
May 19, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 19, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 19, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 9, 2019DOCKASSIGNED TO EXAMINER—
Mar 19, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 4, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance